We used logistic regression to assess effectiveness of primaquine as Plasmodium vivax anti-
relapse therapy using data extracted from studies of P. vivax relapses in Brazil, India, and …

Recent successes in malaria control have put malaria eradication back on the public health
agenda. A significant obstacle to malaria elimination in Asia is the large burden of …

Chloroquine‐resistant Plasmodium vivax has not yet occurred in Vietnam. The efficacy of
artemisinin for P. vivax was not established. We conducted a double‐blind randomized …

Plasmodium vivax infects 130–435 million of the 2.6 billion people living at risk of infection.
Recent studies suggest that vivax malaria can become lethal in a similar way to severe …

Background Plasmodium vivax infections are an important contributor to the malaria burden
worldwide. The World Health Organization recommends a 14‐day course of primaquine …

We assessed monthly doses of tafenoquine for preventing Plasmodium vivax and multidrug-
resistant P. falciparum malaria. In a randomized, double-blind, placebo-controlled study, 205 …

Background Chloroquine is the first-line treatment for Plasmodium vivax malaria in most
endemic countries, but resistance is increasing. Monitoring of antimalarial efficacy is …

Background Plasmodium vivax has the widest geographic distribution of the human malaria
parasites and nearly 2.5 billion people live at risk of infection. The control of P. vivax in …

Tafenoquine is an 8-aminoquinoline under investigation for the prevention of relapse in
Plasmodium vivax malaria. This open-label, dose-escalation study assessed quantitatively …

The gravity of the threat posed by vivax malaria to public health has been poorly
appreciated. The widely held misperception of Plasmodium vivax as being relatively …